Axsome Therapeutics Valuation Reviewed Amid AUVELITY Launch Plans, Earnings

Axsome Therapeutics (AXSM) is under valuation scrutiny following its announced plans to launch AUVELITY for Alzheimer's disease agitation. The company also provided an earnings update, influencing investor perspectives on its future prospects.